<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Acetazolamide: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Acetazolamide: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Acetazolamide: Drug information</div><div class="clear"></div><div id="topicText"><div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
(For additional information <a class="drug drug_patient" data-topicid="12407" href="/d/html/12407.html" rel="external">see "Acetazolamide: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="13213" href="/d/html/13213.html" rel="external">see "Acetazolamide: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F129842"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antiseizure Agent, Miscellaneous;</li>
<li>
                        Carbonic Anhydrase Inhibitor;</li>
<li>
                        Diuretic, Carbonic Anhydrase Inhibitor;</li>
<li>
                        Ophthalmic Agent, Antiglaucoma</li></ul></div>
<div class="block doa drugH1Div" id="F129800"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="dd16fef4-4269-4b7a-b191-7f078cf91f01">Acute mountain sickness/high-altitude cerebral edema</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Acute mountain sickness/high-altitude cerebral edema:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Prevention, moderate- to high-risk situations: </i></b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note: </b>Use in addition to gradual ascent; start the day before (preferred) or on the day of ascent (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20591379']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20591379'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral (immediate release):</b> 125 mg twice daily; may be discontinued after staying at the same elevation for 2 to 4 days or if descent is initiated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20591379']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20591379'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Treatment:</i></b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>
<i>Acute mountain sickness: </i></b></p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Note</b>: For moderate to severe acute mountain sickness, some experts prefer dexamethasone or use acetazolamide as an adjunct to dexamethasone (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Gallagher.2021','lexi-content-ref-20591379']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Gallagher.2021','lexi-content-ref-20591379'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Oral (immediate release):</b> 250 mg twice daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20591379']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20591379'])">Ref</a></span>). Continue until descent or 24 hours after resolution of symptoms. <b>Note: </b>Some experts suggest 125 mg twice daily may be sufficient (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Gallagher.2021']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Gallagher.2021'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>
<i>High-altitude cerebral edema (adjunct): </i></b></p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Oral (immediate release):</b> 250 mg twice daily in combination with dexamethasone (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20591379']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20591379'])">Ref</a></span>). Continue until descent or 24 hours after resolution of symptoms (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Gallagher.2021']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Gallagher.2021'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Although ER dosage formulations are FDA-approved for acute mountain sickness, the lowest available capsule dose (500 mg) exceeds current dosing recommendations for acute mountain sickness/high-altitude cerebral edema (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20591379']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20591379'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="65ef282d-23a6-4668-9e37-3d9d9236ddb8">Edema or general volume overload</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Edema or general volume overload (adjunctive therapy):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note</b>
<b>: </b>Optimize loop diuretic therapy before using adjunctive diuretic therapies; combination diuretic therapy is typically for short-term use to restore euvolemia in patients already taking a high-dose loop diuretic therapy who are resistant (eg, furosemide total daily dose of 160 to 320 mg/day IV or the oral equivalent). Combination diuretic therapy can cause severe electrolyte depletion (eg, potassium, magnesium, sodium); prior to and during therapy, electrolytes should be monitored and appropriately repleted or managed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31526538','lexi-content-ref-35363499','lexi-content-ref-22099505','lexi-content-ref-Brater.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31526538','lexi-content-ref-35363499','lexi-content-ref-22099505','lexi-content-ref-Brater.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV, Oral (immediate release):</b> 250 to 500 mg once daily or every other day; may be administered in combination with or shortly before the scheduled loop diuretic. Assess volume status frequently (eg, daily or at least every 2 to 3 days) to determine effectiveness and to avoid overdiuresis. Continue only until euvolemia is restored (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31526538','lexi-content-ref-22099505','lexi-content-ref-Brater.1','lexi-content-ref-36027559','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31526538','lexi-content-ref-22099505','lexi-content-ref-Brater.1','lexi-content-ref-36027559','lexi-content-ref-Manu.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="3781bc43-f3d3-491d-9b67-5f4a65afc693">Elevated intraocular pressure associated with acute angle-closure glaucoma</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Elevated intraocular pressure associated with acute angle-closure glaucoma (adjunct): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note</b>: To be used when there is a ≥1-hour delay to ophthalmologist evaluation, as an adjunct to topical therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Weizer.2021']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Weizer.2021'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral (immediate release), IV:</b> 500 mg once (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17910297','lexi-content-ref-Weizer.2021']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17910297','lexi-content-ref-Weizer.2021'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="b0f45332-9a77-40ee-ba95-3d6318a68e42">Idiopathic intracranial hypertension</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Idiopathic intracranial hypertension (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral (immediate release, extended release):</b> Initial: 250 to 500 mg twice daily; increase as tolerated by 250 mg every week to reach desired clinical effect or a maximum of 4 g/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26587993','lexi-content-ref-24756514']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26587993','lexi-content-ref-24756514'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1c30d66b-a075-45d3-8536-3439c965273a">Metabolic alkalosis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Metabolic alkalosis (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>In general, use after treatment of underlying causes and replacement of isotonic saline or potassium chloride when appropriate, or when additional fluids are contraindicated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-1894525','lexi-content-ref-Mehta.2021']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-1894525','lexi-content-ref-Mehta.2021'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV (preferred), oral (immediate release): </b>500 mg as a single dose; may repeat as needed based upon acid-base status with 250 to 500 mg up to once or twice daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26836730','lexi-content-ref-10446816','lexi-content-ref-Mehta.2021','lexi-content-ref-28286047']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26836730','lexi-content-ref-10446816','lexi-content-ref-Mehta.2021','lexi-content-ref-28286047'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991665"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Kidney function-adjusted dose recommendations are based on usual doses up to 1 g/day. There are no dosage adjustments necessary for any degree of kidney dysfunction for single doses of 500 mg (ie, elevated intraocular pressure or initial treatment of metabolic alkalosis) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>). Although the manufacturer’s labeling contraindicates use in severe kidney impairment, use may be considered in select patients after careful assessment of risks versus benefits along with close monitoring for adverse effects.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function </b>(<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2498399','lexi-content-ref-9591933','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2498399','lexi-content-ref-9591933','lexi-content-ref-Expert.DOR'])">Ref</a></span>): <b>Oral, IV:</b></p>
<p style="text-indent:-2em;margin-left:4em;">CrCl ≥50 mL/minute: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl 30 to &lt;50 mL/minute:</p>
<p style="text-indent:-2em;margin-left:6em;">Immediate release: 125 to 250 mg twice daily.</p>
<p style="text-indent:-2em;margin-left:6em;">Extended release: Avoid use.</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl 10 to &lt;30 mL/minute:</p>
<p style="text-indent:-2em;margin-left:6em;">Immediate release: Avoid use; acetazolamide accumulation may result in CNS toxicity; if no alternatives available, may consider 125 mg twice daily with close monitoring.</p>
<p style="text-indent:-2em;margin-left:6em;">Extended release: Avoid use.</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl &lt;10 mL/minute:</p>
<p style="text-indent:-2em;margin-left:6em;">Immediate release: Avoid use; acetazolamide accumulation may result in CNS toxicity; if no alternatives available, may consider 125 mg once daily with close monitoring.</p>
<p style="text-indent:-2em;margin-left:6em;">Extended release: Avoid use.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Dialyzable (~30%) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7479208','lexi-content-ref-7367929']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7479208','lexi-content-ref-7367929'])">Ref</a></span>): <b>Oral, IV:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Immediate release: Avoid use; acetazolamide accumulation may result in CNS toxicity; if no alternatives available, may consider 125 mg once daily with close monitoring; when scheduled dose falls on a dialysis day, administer after dialysis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-1462998','lexi-content-ref-7479208']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-1462998','lexi-content-ref-7479208'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Extended release: Avoid use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral, IV:</b> Not significantly dialyzed (6.8%) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7999862']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7999862'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:6em;">Immediate release: Avoid use; acetazolamide accumulation may result in CNS toxicity; if no alternatives available may consider 125 mg once daily with close monitoring (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7999862']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7999862'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Extended release: Avoid use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral, IV:</b> Single doses of 500 mg for elevated intraocular pressure may be considered, otherwise, avoid use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral, IV:</b> Single doses of 500 mg for elevated intraocular pressure may be considered, otherwise, avoid use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50988968"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">Use is contraindicated in patients with cirrhosis or marked liver disease or dysfunction.</p></div>
<div class="block doe drugH1Div" id="F129801"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing. <b>Oral:</b> Initial doses should begin at the low end of the dosage range.</p></div>
<div class="block dop drugH1Div" id="F129820"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="13213" href="/d/html/13213.html" rel="external">see "Acetazolamide: Pediatric drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e940a411-0a19-4506-baae-f3cb106003af">Altitude illness, acute</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Altitude illness, acute:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Prevention: Limited data available: Infants, Children, and Adolescents: Oral: Immediate release: 2.5 mg/kg/dose every 12 hours started either the day before (preferred) or on the day of ascent and may be discontinued after staying at the same elevation for 2 to 3 days or if descent initiated; maximum dose: 125 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20591379']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20591379'])">Ref</a></span>). <b>Note:</b> The International Society for Mountain Medicine does not recommend prophylaxis in children except in the rare circumstance of unavoidable rapid ascent or in children with known previous susceptibility to acute mountain sickness (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11682018']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11682018'])">Ref</a></span>). Higher doses are effective up to 500 mg, but are also associated with increased adverse effects and not recommended (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20591379']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20591379'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Treatment: Acute mountain sickness (AMS); moderate: Limited data available: Infants, Children, and Adolescents: Oral: Immediate release: 2.5 mg/kg/dose every 8 to 12 hours; maximum dose: 250 mg/dose. <b>Note:</b> With high altitude cerebral edema, dexamethasone is the primary treatment; however, acetazolamide may be used adjunctively with the same treatment dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20591379','lexi-content-ref-11682018']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20591379','lexi-content-ref-11682018'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="9c960c2b-b0bf-4a64-8f51-fdc20ee6b0c9">Glaucoma</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Glaucoma:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Children &lt;12 years: Limited data available: Oral: Immediate release: 10 to 30 mg/kg/day divided every 6 to 8 hours; maximum daily dose: 1,000 mg/<b>day</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10532366','lexi-content-ref-17070484']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10532366','lexi-content-ref-17070484'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥12 years and Adolescents: Oral:</p>
<p style="text-indent:-2em;margin-left:6em;">Immediate release: Limited data available: 15 to 30 mg/kg/day in divided doses every 6 to 8 hours; maximum daily dose: 1,000 mg/<b>day</b>.</p>
<p style="text-indent:-2em;margin-left:6em;">Extended release (Diamox sequels):</p>
<p style="text-indent:-2em;margin-left:8em;">Manufacturer's labeling: 500 mg twice daily.</p>
<p style="text-indent:-2em;margin-left:8em;">Alternate dosing: Weight-directed dosing: Limited data available: 15 to 30 mg/kg/day in divided doses twice daily; maximum daily dose: 1,000 mg/<b>day</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Pagliaro.2002','lexi-content-ref-17070484']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Pagliaro.2002','lexi-content-ref-17070484'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="6b3bf4fb-d61c-4d60-acaa-a34bb1a9f68a">Edema</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Edema:</b> Limited data available: Infants, Children, and Adolescents: Oral (immediate release), IV: 5 mg/kg/dose once daily or every other day in the morning (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Park.2014']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Park.2014'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0d3e20bc-4830-490d-b9eb-82784d669053">Epilepsy, short-term management</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Epilepsy, short-term management:</b> Limited data available: Infants, Children, and Adolescents: Oral: Immediate release: Usual range: 4 to 16 mg/kg/day in 3 to 4 divided doses; may titrate; maximum daily dose: 30 mg/kg/<b>day</b> or 1,000 mg/<b>day</b> (whichever is less) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8740334']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8740334'])">Ref</a></span>); <b>Note:</b> Minimal additional benefit with doses &gt;16 mg/kg/day.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1c30d66b-a075-45d3-8536-3439c965273a">Metabolic alkalosis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Metabolic alkalosis:</b> Limited data available; dosing regimens variable: Infants, Children, and Adolescents: IV, Oral (immediate release): 5 mg/kg/dose once daily for 3 doses been used in a prospective trial of postcardiac surgical patients (age range: 8 days to 20 months) and results showed a significant decrease in serum bicarbonate concentrations (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17667206']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17667206'])">Ref</a></span>). A retrospective trial of 34 pediatric patients (mean age: 1.9 years; range: 18 days to 12 years) reported a mean effective dose of 5.4 mg/kg/dose every 6 to 8 hours; a trend showed every 6-hour dosing had a higher success rate but not statistically significant (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24259727']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24259727'])">Ref</a></span>). In adults, the reported dosing is 500 mg as a single dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-1894525','lexi-content-ref-16420662']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-1894525','lexi-content-ref-16420662'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="fc29edc7-db7c-4580-aa4b-39e0accdfb99">Pseudotumor cerebri</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pseudotumor cerebri:</b> Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">Children: Oral: Immediate release: Usual reported initial dose: 15 to 25 mg/kg/day in 2 to 3 divided doses; may increase if needed to a maximum daily dose: 100 mg/kg/<b>day</b> or 2,000 mg/<b>day</b> (whichever is less); therapy continued until resolution of headache, disc swelling, and visual field abnormalities; usually several months (eg, 3 to 9 months) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16368210','lexi-content-ref-22050895','lexi-content-ref-20962512','lexi-content-ref-22981259','lexi-content-ref-18029269','lexi-content-ref-9534686','lexi-content-ref-20721668','lexi-content-ref-21093727']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16368210','lexi-content-ref-22050895','lexi-content-ref-20962512','lexi-content-ref-22981259','lexi-content-ref-18029269','lexi-content-ref-9534686','lexi-content-ref-20721668','lexi-content-ref-21093727'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Adolescents: Oral: Immediate release: Initial: 500 mg twice daily; may increase if needed; maximum daily dose: 4,000 mg/<b>day</b>; usual adult dose range: 1,000 to 4,000 mg/day in 2 to 4 divided doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22668539','lexi-content-ref-21093727']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22668539','lexi-content-ref-21093727'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51010695"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;margin-left:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; acetazolamide is contraindicated in severe renal impairment.</p></div>
<div class="block dohp drugH1Div" id="F51010696"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;margin-left:0em;display:inline">All patients: There are no dosage adjustments provided in the manufacturer's labeling; however, acetazolamide is contraindicated in patients with cirrhosis or severe liver impairment.</p></div>
<div class="block arsc drugH1Div" id="F56225928"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Aplastic anemia</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Case reports of <b>aplastic anemia</b>, including fatalities, have been reported with acetazolamide (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2280240']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2280240'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Non–dose-related; idiosyncratic. May be related to acetazolamide sulfonamide group (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3211478','lexi-content-ref-1543228']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3211478','lexi-content-ref-1543228'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied; has occurred within 7 weeks to a median of 3 months after treatment initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2280240','lexi-content-ref-1451021']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2280240','lexi-content-ref-1451021'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Growth retardation</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Growth retardation</b> (reduced height and/or weight) has been reported in children receiving chronic (&gt;1 year) acetazolamide therapy for adjunctive treatment of seizures in combination with antiseizure medication monotherapy. Growth returned to original level after discontinuation of acetazolamide (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8972532']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8972532'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Related to the pharmacologic action; may result in metabolic acidosis, possibly leading to growth retardation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8972532']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8972532'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hypersensitivity reactions (immediate and delayed)</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Immediate hypersensitivity reactions, including <b>anaphylaxis</b> and <b>urticaria,</b> have been reported with acetazolamide (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29966705','lexi-content-ref-12098191','lexi-content-ref-28089475','lexi-content-ref-1524131','lexi-content-ref-9713074']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29966705','lexi-content-ref-12098191','lexi-content-ref-28089475','lexi-content-ref-1524131','lexi-content-ref-9713074'])">Ref</a></span>). Delayed hypersensitivity reactions range from <b>maculopapular skin rash</b> to rare severe cutaneous adverse reactions, including <b>Stevens-Johnson syndrome</b>, <b>drug reaction with eosinophilia and systemic symptoms</b>, and <b>acute generalized exanthematous pustulosis</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33462002','lexi-content-ref-21342230','lexi-content-ref-23817276','lexi-content-ref-31128378','lexi-content-ref-7327685']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33462002','lexi-content-ref-21342230','lexi-content-ref-23817276','lexi-content-ref-31128378','lexi-content-ref-7327685'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Immediate hypersensitivity reactions: Non–dose-related; immunologic (ie, IgE-mediated, with specific antibodies formed against a drug allergen following initial exposure) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30275849']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30275849'])">Ref</a></span>). Delayed hypersensitivity reactions: Non–dose-related; immunologic (ie, involving a T-cell mediated drug-specific immune response) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31020549']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31020549'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Immediate hypersensitivity reactions: Rapid; generally occurs within 1 hour of administration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12098191','lexi-content-ref-9713074']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12098191','lexi-content-ref-9713074'])">Ref</a></span>) but may occur up to 6 hours after exposure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30558872','lexi-content-ref-NICE.2014']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30558872','lexi-content-ref-NICE.2014'])">Ref</a></span>). Delayed hypersensitivity reactions: Varied; typically occur days to 8 weeks after drug exposure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33462002','lexi-content-ref-26120552','lexi-content-ref-21342230','lexi-content-ref-7327685']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33462002','lexi-content-ref-26120552','lexi-content-ref-21342230','lexi-content-ref-7327685'])">Ref</a></span>), but may occur more rapidly (usually within 1 to 4 days) upon reexposure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26120552']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26120552'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">• Cross-reactivity: Limited published information regarding possible cross-reactivity between acetazolamide and other sulfonamides (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28089475','lexi-content-ref-9713074']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28089475','lexi-content-ref-9713074'])">Ref</a></span>). Cross-reactivity between acetazolamide, a nonantibiotic sulfonamide, and antibiotic sulfonamides is unlikely to occur (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23817276','lexi-content-ref-31495421','lexi-content-ref-15234289','lexi-content-ref-22158718','lexi-content-ref-2334313']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23817276','lexi-content-ref-31495421','lexi-content-ref-15234289','lexi-content-ref-22158718','lexi-content-ref-2334313'])">Ref</a></span>). Cross-reactivity among carbonic anhydrase inhibitors is unknown.</p>
<p style="text-indent:-2em;margin-left:6em;">• Ethnicity: Increased risk in patients of Korean, Chinese, and Japanese descent (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21342230','lexi-content-ref-31128378','lexi-content-ref-31706497']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21342230','lexi-content-ref-31128378','lexi-content-ref-31706497'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Metabolic acidosis</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Acetazolamide use has been associated with <b>metabolic acidosis</b>, which may lead to treatment discontinuation and, in some cases, death (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12203177','lexi-content-ref-26824595','lexi-content-ref-11149457']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12203177','lexi-content-ref-26824595','lexi-content-ref-11149457'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Related to pharmacologic action. Prevents bicarbonate reabsorption in the renal tubules, leading to metabolic acidosis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32332024','lexi-content-ref-26824595','lexi-content-ref-11149457']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32332024','lexi-content-ref-26824595','lexi-content-ref-11149457'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Rapid; typically occurs within 2 to 4 days of therapy initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12203177','lexi-content-ref-11149457']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12203177','lexi-content-ref-11149457'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Diabetes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11149457']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11149457'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Kidney impairment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12203177']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12203177'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Older adults (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11149457']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11149457'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Uncompensated or severe COPD (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32241707']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32241707'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Paresthesia</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Acetazolamide use has been associated with <b>paresthesia</b>, which may limit tolerability and lead to nonadherence (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32332024','lexi-content-ref-26587993','lexi-content-ref-11985388']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32332024','lexi-content-ref-26587993','lexi-content-ref-11985388'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Dose-related; may result in metabolic acidosis, possibly leading to paresthesia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32332024']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32332024'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Higher doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32332024']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32332024'])">Ref</a></span>)</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F129763"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Flushing</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Allergic skin reaction, skin photosensitivity</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Electrolyte disorder, glycosuria, hyperglycemia, hypoglycemia, hypokalemia, hyponatremia</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Decreased appetite, diarrhea, dysgeusia, melena, nausea, vomiting</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Crystalluria, hematuria</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Immune thrombocytopenia, leukopenia</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Abnormal hepatic function tests, cholestatic jaundice, fulminant hepatic necrosis, hepatic insufficiency</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Pain at injection site</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Ataxia, confusion, depression, dizziness, drowsiness, excitement, fatigue, flaccid paralysis, headache, malaise</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: Auditory disturbance, tinnitus</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Polyuria</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Acute generalized exanthematous pustulosis (Jachiet 2013), maculopapular rash (Jachiet 2013), Stevens-Johnson syndrome (Her 2011), toxic epidermal necrolysis (Kim 2019), urticaria (Carlisle 2018)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Growth retardation (children) (Futagi 1996), metabolic acidosis (Venkatesha 2000)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Agranulocytosis (Incecik 2020), aplastic anemia (Keisu 1990), thrombocytopenia (Kodjikian 2004)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis (Gallerani 2002)</p>
<p style="text-indent:-2em;margin-left:4em;">Immunologic: Drug reaction with eosinophilia and systemic symptoms (Ali 2021)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Paresthesia (Schmickl 2020)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Acute angle-closure glaucoma (Bayer 2010), choroidal effusion (Bayer 2010), myopia (Hill 2016)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Renal failure syndrome (Higenbottam 1978)</p></div>
<div class="block coi drugH1Div" id="F129780"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to acetazolamide, sulfonamides, or any component of the formulation; marked hepatic disease or insufficiency; decreased sodium and/or potassium levels; adrenocortical insufficiency; cirrhosis; hyperchloremic acidosis; severe renal disease or dysfunction; long-term use in noncongestive angle-closure glaucoma</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Although the FDA-approved product labeling states this medication is contraindicated in patients with hypersensitivity to sulfonamide-containing drugs, the scientific basis of this cross-sensitivity has been challenged. See “Warnings/Precautions” for more detail. Additionally, although the manufacturer’s labeling contraindicates use in severe kidney impairment, use may be considered in select patients after careful assessment of risks versus benefits along with close monitoring for adverse effects.</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<i>Canadian labeling</i>: Additional contraindications not in US labeling: Hemorrhagic glaucoma; glaucoma due to peripheral anterior synechias; metabolic acidosis.</p></div>
<div class="block war drugH1Div" id="F129760"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks that require mental alertness (eg, operating machinery or driving).</p>
<p style="text-indent:-2em;margin-left:4em;">• Sulfonamide (“sulfa”) allergy: The FDA-approved product labeling for many medications containing a sulfonamide chemical group includes a broad contraindication in patients with a prior allergic reaction to sulfonamides. There is a potential for cross-reactivity between members of a specific class (eg, two antibiotic sulfonamides). However, concerns for cross-reactivity have previously extended to all compounds containing the sulfonamide structure (SO<sub>2</sub>NH<sub>2</sub>). An expanded understanding of allergic mechanisms indicates cross-reactivity between antibiotic sulfonamides and nonantibiotic sulfonamides may not occur or at the very least this potential is extremely low (Brackett 2004; Johnson 2005; Slatore 2004; Tornero 2004). In particular, mechanisms of cross-reaction due to antibody production (anaphylaxis) are unlikely to occur with nonantibiotic sulfonamides. T-cell-mediated (type IV) reactions (eg, maculopapular rash) are not well understood and it is not possible to completely exclude this potential based on current insights. In cases where prior reactions were severe (Stevens-Johnson syndrome/TEN), some clinicians choose to avoid exposure to these classes.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Diabetes: Use with caution in patients with prediabetes or diabetes mellitus; may see a change in glucose control.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in patients with hepatic dysfunction; in cirrhosis, avoid electrolyte and acid/base imbalances that might lead to hepatic encephalopathy.</p>
<p style="text-indent:-2em;margin-left:4em;">• Respiratory acidosis: Use with caution in patients with respiratory acidosis; may worsen acidosis.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Older adult: Use with caution in the elderly; may be more sensitive to side effects.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Increasing the dose does not increase diuresis and may increase the incidence of drowsiness and/or paresthesia; often results in a reduction of diuresis.</p>
<p style="text-indent:-2em;margin-left:4em;">• IM administration: Painful because of the alkaline pH of the drug; use by this route is not recommended.</p></div>
<div class="block foc drugH1Div" id="F129772"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule Extended Release 12 Hour, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 500 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Injection: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 500 mg (1 ea)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Injection [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 500 mg (1 ea)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 125 mg, 250 mg</p></div>
<div class="block geq drugH1Div" id="F129756"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F129782"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsule, 12-hour</b> (acetaZOLAMIDE ER Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">500 mg (per each): $0.82 - $4.29</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (acetaZOLAMIDE Sodium Injection)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">500 mg (per each): $39.38 - $52.75</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (acetaZOLAMIDE Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">125 mg (per each): $0.31 - $2.18</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">250 mg (per each): $0.42 - $6.65</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52865540"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Injection: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 500 mg (1 ea)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 250 mg</p></div>
<div class="block adm drugH1Div" id="F129776"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral:</b> May be administered with food.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>IM:</b> IM administration is painful because of the alkaline pH of the drug; use by this route is not recommended.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV:</b> Direct IV injection is the preferred parenteral route of administration. Specific IV push rates are not provided in the manufacturer's labeling. However, an IV push rate of up to 500 mg over 3 minutes has been reported in a clinical trial (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10446816']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10446816'])">Ref</a></span>). Additionally, a study to assess cerebrovascular reserve used a rapid IV push of up to 1 g over ≤1 minute (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2204147']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2204147'])">Ref</a></span>).</p></div>
<div class="block admp drugH1Div" id="F52612176"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Oral: Administer with food to decrease GI upset. Immediate-release tablets may be crushed and suspended in cherry or chocolate syrup to disguise the bitter taste of the drug; alternatively, submerge tablet in 10 mL of hot water and add 10 mL honey or syrup.</p>
<p style="text-indent:-2em;margin-left:2em;">Parenteral:</p>
<p style="text-indent:-2em;margin-left:4em;">IV: Direct IV injection is the preferred parenteral route of administration. Specific IV push rates are not provided in the manufacturer's labeling. In an adult trial, IV push rate of 500 mg over 3 minutes was used (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10446816']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10446816'])">Ref</a></span>); some have recommended a maximum rate of 500 mg/minute (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Gahart.2014']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Gahart.2014'])">Ref</a></span>). Additionally, a study in adults to assess cerebrovascular reserve used a rapid IV push of up to 1 g over ≤1 minute (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2204147']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2204147'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">IM: Not recommended as the drug's alkaline pH makes it very painful</p></div>
<div class="block use drugH1Div" id="F129775"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Acute mountain sickness/high-altitude cerebral edema:</b> Prevention or treatment of symptoms associated with acute mountain sickness (AMS) (IR dosage forms). <b>Note: </b>High-altitude cerebral edema (HACE) is considered a severe form of AMS. Although ER dosage formulations are FDA-approved for AMS, the lowest available capsule dose (500 mg) exceeds current dosing recommendations for AMS/HACE (WMS [Luks 2019]).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Edema</b>
<b> or general volume overload:</b> Adjunctive treatment of drug-induced edema or edema due to heart failure.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Elevated intraocular pressure </b>
<b>associated with acute angle-closure glaucoma:</b> Treatment of elevated intraocular pressure in patients with acute angle-closure glaucoma prior to surgery or as part of a combination regimen when a patient cannot be seen by an ophthalmologist for ≥1 hour.</p></div>
<div class="block off-label drugH1Div" id="F25720644"><span class="drugH1">Use: Off-Label: Adult</span><p>Idiopathic intracranial hypertension; Metabolic alkalosis</p></div>
<div class="block mst drugH1Div" id="F129850"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">AcetaZOLAMIDE may be confused with acetaminophen</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">International issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Diamox [Canada and multiple international markets] may be confused with Diabinese brand name for chlorpropamide [Multiple international markets]; Dobutrex brand name for dobutamine [Multiple international markets]; Trimox brand name for amoxicillin [Brazil]; Zimox brand name for amoxicillin [Italy] and carbidopa/levodopa [Greece]</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F129837"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F129765"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Ajmaline: Sulfonamides may enhance the adverse/toxic effect of Ajmaline. Specifically, the risk for cholestasis may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alpha-/Beta-Agonists (Indirect-Acting): Carbonic Anhydrase Inhibitors may increase the serum concentration of Alpha-/Beta-Agonists (Indirect-Acting). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amantadine: Carbonic Anhydrase Inhibitors may increase the serum concentration of Amantadine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amphetamines: Carbonic Anhydrase Inhibitors may decrease the excretion of Amphetamines. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Carbonic Anhydrase Inhibitors: May enhance the adverse/toxic effect of other Carbonic Anhydrase Inhibitors. The development of acid-base disorders with concurrent use of ophthalmic and oral carbonic anhydrase inhibitors has been reported. Management: Avoid concurrent use of different carbonic anhydrase inhibitors if possible.  Monitor patients closely for the occurrence of kidney stones and with regards to severity of metabolic acidosis.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CycloSPORINE (Systemic): AcetaZOLAMIDE may increase the serum concentration of CycloSPORINE (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Desmopressin: Hyponatremia-Associated Agents may enhance the hyponatremic effect of Desmopressin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dexketoprofen: May enhance the adverse/toxic effect of Sulfonamides.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Diacerein: May enhance the therapeutic effect of Diuretics. Specifically, the risk for dehydration or hypokalemia may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flecainide: Carbonic Anhydrase Inhibitors may decrease the excretion of Flecainide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fosphenytoin-Phenytoin: Carbonic Anhydrase Inhibitors may enhance the adverse/toxic effect of Fosphenytoin-Phenytoin. Specifically, the risk for osteomalacia or rickets may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lithium: Carbonic Anhydrase Inhibitors may decrease the serum concentration of Lithium. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mecamylamine: Sulfonamides may enhance the adverse/toxic effect of Mecamylamine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mefloquine: May diminish the therapeutic effect of Antiseizure Agents. Mefloquine may decrease the serum concentration of Antiseizure Agents. Management: Mefloquine is contraindicated for malaria prophylaxis in persons with a history of seizures. If antiseizure drugs are being used for another indication, monitor antiseizure drug concentrations and treatment response closely with concurrent use.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Memantine: Carbonic Anhydrase Inhibitors may increase the serum concentration of Memantine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">MetFORMIN: Carbonic Anhydrase Inhibitors may enhance the adverse/toxic effect of MetFORMIN. Specifically, the risk of developing lactic acidosis may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methenamine: Carbonic Anhydrase Inhibitors may diminish the therapeutic effect of Methenamine.  Management: Consider avoiding the concomitant use of medications that alkalinize the urine, such as carbonic anhydrase inhibitors, and methenamine. Monitor for decreased therapeutic effects of methenamine if used concomitant with a carbonic anhydrase inhibitor.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">MetyraPONE: Antiseizure Agents may diminish the diagnostic effect of MetyraPONE.  Management: Consider alternatives to the use of the metyrapone test in patients taking antiseizure agents.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mianserin: May diminish the therapeutic effect of Antiseizure Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mivacurium: AcetaZOLAMIDE may enhance the therapeutic effect of Mivacurium. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Opioid Agonists: May enhance the adverse/toxic effect of Diuretics. Opioid Agonists may diminish the therapeutic effect of Diuretics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Orlistat: May decrease the serum concentration of Antiseizure Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Polyethylene Glycol-Electrolyte Solution: Diuretics may enhance the nephrotoxic effect of Polyethylene Glycol-Electrolyte Solution. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Salicylates: May enhance the adverse/toxic effect of Carbonic Anhydrase Inhibitors. Salicylate toxicity might be enhanced by this same combination. Management: Avoid these combinations when possible.Dichlorphenamide use with high-dose aspirin as contraindicated. If another combination is used, monitor patients closely for adverse effects. Tachypnea, anorexia, lethargy, and coma have been reported.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium Bicarbonate (Systemic): AcetaZOLAMIDE may enhance the adverse/toxic effect of Sodium Bicarbonate (Systemic). Specifically, the risk of renal calculus formation may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium Phosphates: Diuretics may enhance the nephrotoxic effect of Sodium Phosphates. Specifically, the risk of acute phosphate nephropathy may be enhanced. <i> Risk C: Monitor therapy</i></p></div>
<div class="block pri drugH1Div" id="F129783"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Limited data is available following the use of acetazolamide in pregnant women for the treatment of idiopathic intracranial hypertension (Falardeau 2013; Kesler 2013).</p>
<p style="text-indent:0em;margin-top:2em;">Pregnant women exposed to acetazolamide during pregnancy for the treatment of seizure disorders are encouraged to enroll themselves into the AED Pregnancy Registry by calling 1-888-233-2334. Additional information is available at https://www.aedpregnancyregistry.org.</p></div>
<div class="block brc drugH1Div" id="F10912707"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Acetazolamide is present in breast milk. In a case report, low concentrations of acetazolamide were detected in the breast milk and the infant serum following a maternal dose of acetazolamide 500 mg twice daily. Acetazolamide concentrations in the breast milk were 1.3 to 2.1 mcg/mL, 1 to 9 hours after the dose. Acetazolamide concentrations in the infant serum were 0.2 to 0.6 mcg/mL, 2 to 12 hours after nursing. Maternal plasma concentrations were 5.2 to 6.4 mcg/mL, 1 to 7 hours after the dose. All levels were obtained on days 4 to 5 of therapy, 10 days after delivery (Söderman 1984). Due to the potential for serious adverse reactions in the breastfed infant, the manufacturer recommends a decision be made whether to discontinue breastfeeding or to discontinue the drug, taking into account the importance of treatment to the mother.</p></div>
<div class="block dic drugH1Div" id="F129784"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">May be taken with food to decrease GI upset. May have additive effects with other folic acid antagonists. Some products may contain sodium.</p></div>
<div class="block mop drugH1Div" id="F129770"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Intraocular pressure (30 to 60 minutes after administration for acute angle-closure glaucoma (Pokhrel 2007; Weizer 2021); serum electrolytes; periodic CBC with differential; monitor growth in pediatric patients.</p></div>
<div class="block pha drugH1Div" id="F129759"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Reversible inhibition of the enzyme carbonic anhydrase resulting in reduction of hydrogen ion secretion at renal tubule and an increased renal excretion of sodium, potassium, bicarbonate, and water. Decreases production of aqueous humor and inhibits carbonic anhydrase in central nervous system to retard abnormal and excessive discharge from CNS neurons.</p></div>
<div class="block phk drugH1Div" id="F129779"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Onset of action: Capsule (extended release): 2 hours; Tablet (immediate release): 1 to 1.5 hours; IV: 2 to 10 minutes</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Peak effect: Capsule (extended release): 8 to 18 hours; IV: 15 minutes; Tablet: 2 to 4 hours </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Duration: Inhibition of aqueous humor secretion: Capsule (extended release): 18 to 24 hours; IV: 4 to 5 hours; Tablet: 8 to 12 hours </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Absorption: Appears to be dose dependent; erratic with daily doses &gt;10 mg/kg </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Distribution: Erythrocytes, kidneys; blood-brain barrier</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Protein binding: 95% </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Half-life: 2.4 to 5.8 hours </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Time to peak, plasma: Capsule (extended release): 3 to 6 hours; Tablet: 1 to 4 hours; IV: 15 minutes</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Excretion: Urine (70% to 100% [IV, tablet], 47% [extended release capsule] as unchanged drug within 24 hours)</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F129785"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Apo acetazolamide | Diamox</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Aceta | Diabo | Diamox | Hydroftal | Matro</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Acetazolamid | Diamox</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Diamox</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Acemox | Edimox | Remox</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Diamox</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Dehydratin</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Diamox | Zolamox</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Diamox | Glaupax</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Acetazolamida | Diamox</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Acetazolamida | Diamox | Glaucomed | Viclear</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Diluran</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Acemit | Diamox | Diuramid | Glaupax</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Aceta Diazol | Diamox | Oculten</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Acetazolamida Kronos | Diamox | Glaucomed</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Acemide | Acemit | Diacarb | Diamox | Diuramid</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Acetamox | Cidamex</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Edemox</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Diamox | Oedemin | Oratrol</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Diamox</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Acetazolamide dc | Diamox | Eytazox</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Diamox | Edemox</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Apo acetazolamide | Diamox</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Acetazolamid Agepha | Diamox</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Huma-zolamide</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Diamox | Glaucon | Glaupax | Glauseta</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Diamox | Glaupax</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Diamox | Uramox</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Aceact | Actamid | Avva | Diamox | Diamox er | Glumox | I.p.c | Iopar | P 20 | Trymox | Zolamide</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Diamox</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Admox | Diamox</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Acetamox | Ailopan | Betaurel nitten | Betaurel seiko | Diamox | Diamox sanken | Didoc | Ditmune | Sethamid</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Acetamox</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Acetazol | Diamox</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Diamox</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Apo acetazolamide | Diamox</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Dehydratin | Diacarb | Diamox</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Diamox</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Dehydratin | Diacarb</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Diamox</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Aceta Diazol | Acetazolamida | Akezol | Diamox</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Acetomid | Apo acetazolamide | Diamox</span>;</li>
<li>
<span class="countryCode">(NG)</span> <span class="country">Nigeria</span><span class="countrySeparator">: </span><span class="drugName">Axytex | Dilamox | Klydamox</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Diamox | Glaupax</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Diamox | Diamox unimedic | Glaupax | Glaupax unimedic</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Diamox</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Acetak | Acetazolamida | Apo acetazolamida | Diacetaz | Diamox | Glaucozol</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Diamox | Zolmide</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Acemit | Acemox | Azm | Diamox | Evamox | Setacar</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Diamox | Diuramid</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Acetazolamide | Diamox</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Acetazolamida | Carbinib | Lediamox</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Stazol</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Acetazolamida arena | Ederen</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Diacarb</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Apo acetazolamide | Diamox</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Diamox | Glaupax</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Apo acetazolamide | Diamox</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Acetazolamid | Diamox | Edemox</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Diluran</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Diamox | Glaupax | Medene</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Diamox</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Diazomid</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Acetazolamax | Atenezol | Azol | Diamox</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Diacarb | Radicarb</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Acetak | Diamox | Diural</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Acetazolamida | Diamox</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Azomid | Diamox</span>;</li>
<li>
<span class="countryCode">(ZW)</span> <span class="country">Zimbabwe</span><span class="countrySeparator">: </span><span class="drugName">Apo acetazolamide</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-Avet.1">
<a name="Avet.1"></a>Acetazolamide extended release capsules [prescribing information]. East Brunswick, NJ: Avet Pharmaceuticals Inc; November 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Avet.2">
<a name="Avet.2"></a>Acetazolamide injection [prescribing information]. East Brunswick, NJ: Avet Pharma; February 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Sagent.1">
<a name="Sagent.1"></a>Acetazolamide injection [prescribing information]. Schaumberg, IL: Sagent Pharmaceuticals; February 2013.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Novitium.1">
<a name="Novitium.1"></a>Acetazolamide tablets, USP [prescribing information]. East Windsor, NJ: Novitium Pharma LLC; February 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-AAPharma.1">
<a name="AAPharma.1"></a>Acetazolamide tablets [product monograph]. Vaughn, Ontario, Canada: AA Pharma Inc; May 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33462002">
<a name="33462002"></a>Ali SB, Schweikert S, Brusch A. Drug reaction with eosinophilia and systemic symptoms syndrome secondary to acetazolamide associated with markedly elevated procalcitonin. <i>BMJ Case Rep</i>. 2021;14(1):e236966. doi:10.1136/bcr-2020-236966<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acetazolamide-drug-information/abstract-text/33462002/pubmed" id="33462002" target="_blank">33462002</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-AAO.1">
<a name="AAO.1"></a>American Academy of Ophthalmology. Primary open-angle glaucoma preferred practice pattern. https://www.aao.org/preferred-practice-pattern/primary-open-angle-glaucoma-ppp. Published September 12, 2020. Accessed June 10, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24259727">
<a name="24259727"></a>Andrews MG, Johnson PN, Lammers EM, Harrison DL, Miller JL. Acetazolamide in critically ill neonates and children with metabolic alkalosis. <i>Ann Pharmacother</i>. 2013;47(9):1130-1135.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acetazolamide-drug-information/abstract-text/24259727/pubmed" id="24259727" target="_blank">24259727</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Aronoff.2007">
<a name="Aronoff.2007"></a>Aronoff GR, Bennett WM, Berns JS, et al, <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>, 5th ed. Philadelphia, PA: American College of Physicians; 2007, p 97.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Bayer.2010">
<a name="Bayer.2010"></a>Bayer A, Moroi SE. Acetazolamide and bilateral uveal effusion with secondary acute angle-closure glaucoma. <i>Glaucoma Today</i>. Published April 2010.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31020549">
<a name="31020549"></a>Bellón T. Mechanisms of severe cutaneous adverse reactions: Recent advances. <i>Drug Saf</i>. 2019;42(8):973-992. doi:10.1007/s40264-019-00825-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acetazolamide-drug-information/abstract-text/31020549/pubmed" id="31020549" target="_blank">31020549</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30558872">
<a name="30558872"></a>Blumenthal KG, Peter JG, Trubiano JA, Phillips EJ. Antibiotic allergy. <i>Lancet</i>. 2019;393(10167):183-198. doi:10.1016/S0140-6736(18)32218-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acetazolamide-drug-information/abstract-text/30558872/pubmed" id="30558872" target="_blank">30558872</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15303450">
<a name="15303450"></a>Brackett CC, Singh H, Block JH. Likelihood and mechanisms of cross-allergenicity between sulfonamide antibiotics and other drugs containing a sulfonamide functional group. <i>Pharmacotherapy</i>. 2004;24(7):856-870.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acetazolamide-drug-information/abstract-text/15303450/pubmed" id="15303450" target="_blank">15303450</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Brater.1">
<a name="Brater.1"></a>Brater DC. Causes and treatment of refractory edema in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed December 4, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22099505">
<a name="22099505"></a>Brater DC. Update in diuretic therapy: clinical pharmacology. <i>Semin Nephrol</i>. 2011;31(6):483-494. doi:10.1016/j.semnephrol.2011.09.003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acetazolamide-drug-information/abstract-text/22099505/pubmed" id="22099505" target="_blank">22099505</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26120552">
<a name="26120552"></a>Brockow K, Przybilla B, Aberer W, et al. Guideline for the diagnosis of drug hypersensitivity reactions: S2K-Guideline of the German Society for Allergology and Clinical Immunology (DGAKI) and the German Dermatological Society (DDG) in collaboration with the Association of German Allergologists (AeDA), the German Society for Pediatric Allergology and Environmental Medicine (GPA), the German Contact Dermatitis Research Group (DKG), the Swiss Society for Allergy and Immunology (SGAI), the Austrian Society for Allergology and Immunology (ÖGAI), the German Academy of Allergology and Environmental Medicine (DAAU), the German Center for Documentation of Severe Skin Reactions and the German Federal Institute for Drugs and Medical Products (BfArM). <i>Allergo J Int</i>. 2015;24(3):94-105. doi:10.1007/s40629-015-0052-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acetazolamide-drug-information/abstract-text/26120552/pubmed" id="26120552" target="_blank">26120552</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29966705">
<a name="29966705"></a>Carlisle A, Kennedy JL, Chervinskiy S, Jones SM, Pesek RD. Successful desensitization in a pediatric patient with acetazolamide allergy. <i>Ann Allergy Asthma Immunol</i>. 2018;121(4):508-509. doi:10.1016/j.anai.2018.06.024<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acetazolamide-drug-information/abstract-text/29966705/pubmed" id="29966705" target="_blank">29966705</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2498399">
<a name="2498399"></a>Chapron DJ, Gomolin IH, Sweeney KR. Acetazolamide blood concentrations are excessive in the elderly: propensity for acidosis and relationship to renal function. <i>J Clin Pharmacol</i>. 1989;29(4):348-353. doi:10.1002/j.1552-4604.1989.tb03340.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acetazolamide-drug-information/abstract-text/2498399/pubmed" id="2498399" target="_blank">2498399</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3986087">
<a name="3986087"></a>Chapron DJ, Sweeney KR, Feig PU, et al, “Influence of Advanced Age on the Disposition of Acetazolamide,” <i>Br J Clin Pharmacol</i>, 1985, 19:363-71.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acetazolamide-drug-information/abstract-text/3986087/pubmed" id="3986087" target="_blank">3986087</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32241707">
<a name="32241707"></a>Cole JL. Acetazolamide causes worsening acidosis in uncompensated COPD exacerbations: increased awareness needed for patient safety. <i>J Emerg Med</i>. 2020;58(6):953-958. doi:10.1016/j.jemermed.2020.01.019<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acetazolamide-drug-information/abstract-text/32241707/pubmed" id="32241707" target="_blank">32241707</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Diamox.1">
<a name="Diamox.1"></a>Diamox Sequels (acetazolamide) [prescribing information]. Pomona, NY: Duramed Pharmaceuticals, Inc; July 2008.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16368210">
<a name="16368210"></a>Distelmaier F, Sengler U, Messing-Juenger M, et al. <i>Pseudotumor cerebri</i> as an important differential diagnosis of papilledema in children. <i>Brain and Development</i>. 2006;28:190-195.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acetazolamide-drug-information/abstract-text/16368210/pubmed" id="16368210" target="_blank">16368210</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26836730">
<a name="26836730"></a>Faisy C, Meziani F, Planquette B, et al. Effect of acetazolamide vs placebo on duration of invasive mechanical ventilation among patients with chronic obstructive pulmonary disease: a randomized clinical trial. <i>JAMA</i>. 2016;315(5):480-488. doi:10.1001/jama.2016.0019<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acetazolamide-drug-information/abstract-text/26836730/pubmed" id="26836730" target="_blank">26836730</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22635167">
<a name="22635167"></a>Falardeau J, Lobb BM, Golden S, et al, "The Use of Acetazolamide During Pregnancy in Intracranial Hypertension Patients," <i>J Neuroophthalmol</i>, 2013, 33(1):9-12.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acetazolamide-drug-information/abstract-text/22635167/pubmed" id="22635167" target="_blank">22635167</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26934393">
<a name="26934393"></a>Funder JW, Carey RM, Mantero F, et al. The management of primary aldosteronism: case detection, diagnosis, and treatment: an Endocrine Society Clinical Practice Guideline. <i>J Clin Endocrinol Metab</i>. 2016;101(5):1889-1916. doi: 10.1210/jc.2015-4061.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acetazolamide-drug-information/abstract-text/26934393/pubmed" id="26934393" target="_blank">26934393</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8972532">
<a name="8972532"></a>Futagi Y, Otani K, Abe J. Growth suppression in children receiving acetazolamide with antiepileptic drugs. <i>Pediatr Neurol</i>. 1996;15(4):323-326. doi:10.1016/s0887-8994(96)00228-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acetazolamide-drug-information/abstract-text/8972532/pubmed" id="8972532" target="_blank">8972532</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Gahart.2014">
<a name="Gahart.2014"></a>Gahart BL, Nazareno AR. <i>2014 Intravenous Medications: A Handbook for Nurses and Health Professionals</i>. 30th ed. St Louis, MO: Elsevier/Mosby; 2014.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Gallagher.2021">
<a name="Gallagher.2021"></a>Gallagher SA, Hackett P. Acute mountain sickness and high altitude cerebral edema. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed November 1, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12098191">
<a name="12098191"></a>Gallerani M, Manzoli N, Fellin R, Simonato M, Orzincolo C. Anaphylactic shock and acute pulmonary edema after a single oral dose of acetazolamide. <i>Am J Emerg Med</i>. 2002;20(4):371-372. doi:10.1053/ajem.2002.33774<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acetazolamide-drug-information/abstract-text/12098191/pubmed" id="12098191" target="_blank">12098191</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28089475">
<a name="28089475"></a>Gharib A, Khokhar A, Caperton CV, Hamadani ST. Desensitization to acetazolamide in a patient with previous antimicrobial sulfonamide allergy. <i>Ann Allergy Asthma Immunol</i>. 2017;118(3):369-370. doi:10.1016/j.anai.2016.11.029<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acetazolamide-drug-information/abstract-text/28089475/pubmed" id="28089475" target="_blank">28089475</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22050895">
<a name="22050895"></a>Hacifazlioglu N, Yilmaz Y. <i>Pseudotumour cerebri</i> in children: etiological, clinical features and treatment modalities. <i>European Journal of Paediatric Neurology</i>. 2012;12:349-355.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acetazolamide-drug-information/abstract-text/22050895/pubmed" id="22050895" target="_blank">22050895</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35363499">
<a name="35363499"></a>Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines. <i>Circulation</i>. 2022;145(18):e895-e1032. doi:10.1161/CIR.0000000000001063<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acetazolamide-drug-information/abstract-text/35363499/pubmed" id="35363499" target="_blank">35363499</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-4037942">
<a name="4037942"></a>Heller I, Halevy J, Cohen S, et al, “Significant Metabolic Acidosis Induced by Acetazolamide,” <i>Arch Intern Med</i>, 1985, 145(10):1815-7.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acetazolamide-drug-information/abstract-text/4037942/pubmed" id="4037942" target="_blank">4037942</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21342230">
<a name="21342230"></a>Her Y, Kil MS, Park JH, Kim CW, Kim SS. Stevens-Johnson syndrome induced by acetazolamide. <i>J Dermatol</i>. 2011;38(3):272-275. doi:10.1111/j.1346-8138.2010.00921.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acetazolamide-drug-information/abstract-text/21342230/pubmed" id="21342230" target="_blank">21342230</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-634875">
<a name="634875"></a>Higenbottam T, Ogg CS, Saxton HM. Acute renal failure from the use of acetazolamide (Diamox). <i>Postgrad Med J</i>. 1978;54(628):127-128. doi:10.1136/pgmj.54.628.127<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acetazolamide-drug-information/abstract-text/634875/pubmed" id="634875" target="_blank">634875</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27397528">
<a name="27397528"></a>Hill AD. Myopic changes in a climber after taking acetazolamide and the use of corrective lenses to temporize symptoms: a case report from Mount Kilimanjaro. <i>Wilderness Environ Med</i>. 2016;27(3):397-400. doi:10.1016/j.wem.2016.04.002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acetazolamide-drug-information/abstract-text/27397528/pubmed" id="27397528" target="_blank">27397528</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31526538">
<a name="31526538"></a>Hollenberg SM, Warner Stevenson L, Ahmad T, et al. 2019 ACC expert consensus decision pathway on risk assessment, management, and clinical trajectory of patients hospitalized with heart failure: a report of the American College of Cardiology Solution Set Oversight Committee.<i> J Am Coll Cardiol</i>. 2019;74(15):1966-2011. doi:10.1016/j.jacc.2019.08.001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acetazolamide-drug-information/abstract-text/31526538/pubmed" id="31526538" target="_blank">31526538</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33623291">
<a name="33623291"></a>Incecik F, Ozcan N, Ozcanyuz DG, Mert GG. Acetazolamide-induced agranulocytosis in a patient with <i>Pseudotumor cerebri</i>. <i>Ann Indian Acad Neurol</i>. 2020;23(5):732-733. doi:10.4103/aian.AIAN_58_19<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acetazolamide-drug-information/abstract-text/33623291/pubmed" id="33623291" target="_blank">33623291</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23817276">
<a name="23817276"></a>Jachiet M, Bellon N, Assier H, et al. Cutaneous adverse drug reaction to oral acetazolamide and skin tests. <i>Dermatology</i>. 2013;226(4):347-352. doi:10.1159/000350939<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acetazolamide-drug-information/abstract-text/23817276/pubmed" id="23817276" target="_blank">23817276</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15644481">
<a name="15644481"></a>Johnson KK, Green DL, Rife JP, Limon L. Sulfonamide cross-reactivity: fact or fiction? [published correction appears in <i>Ann Pharmacother</i>. 2005;39(7-8):1373]. A<i>nn Pharmacother</i>. 2005;39(2):290-301.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acetazolamide-drug-information/abstract-text/15644481/pubmed" id="15644481" target="_blank">15644481</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2280240">
<a name="2280240"></a>Keisu M, Wiholm BE, Ost A, Mortimer O. Acetazolamide-associated aplastic anaemia. <i>J Intern Med</i>. 1990;228(6):627-632. doi:10.1111/j.1365-2796.1990.tb00290.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acetazolamide-drug-information/abstract-text/2280240/pubmed" id="2280240" target="_blank">2280240</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23563883">
<a name="23563883"></a>Kesler A and Kupferminc M, "Idiopathic Intracranial Hypertension and Pregnancy," <i>Clin Obstet Gynecol</i>, 2013, 56(2):389-96.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acetazolamide-drug-information/abstract-text/23563883/pubmed" id="23563883" target="_blank">23563883</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31495421">
<a name="31495421"></a>Khan DA, Knowles SR, Shear NH. Sulfonamide hypersensitivity: Fact and Fiction. <i>J Allergy Clin Immunol Pract</i>. 2019;7(7):2116-2123. doi:10.1016/j.jaip.2019.05.034<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acetazolamide-drug-information/abstract-text/31495421/pubmed" id="31495421" target="_blank">31495421</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31128378">
<a name="31128378"></a>Kim S, Yun J, Kang DY, et al. Carbonic anhydrase inhibitor-induced Stevens-Johnson syndrome/toxic epidermal necrolysis leads to extensive cutaneous involvement. <i>J Allergy Clin Immunol Pract</i>. 2019;7(8):2851-2853.e2. doi:10.1016/j.jaip.2019.05.01<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acetazolamide-drug-information/abstract-text/31128378/pubmed" id="31128378" target="_blank">31128378</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20962512">
<a name="20962512"></a>Ko MW,Liu GT. Pediatric idiopathic intracranial hypertension (<i>Pseudotumor cerebri</i>). <i>Horm Res Paediatr</i>. 2010;74:381-389.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acetazolamide-drug-information/abstract-text/20962512/pubmed" id="20962512" target="_blank">20962512</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15477470">
<a name="15477470"></a>Kodjikian L, Durand B, Burillon C, Rouberol F, Grange JD, Renaudier P. Acetazolamide-induced thrombocytopenia. <i>Arch Ophthalmol</i>. 2004;122(10):1543-1544. doi:10.1001/archopht.122.10.1543<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acetazolamide-drug-information/abstract-text/15477470/pubmed" id="15477470" target="_blank">15477470</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15234289">
<a name="15234289"></a>Lee AG, Anderson R, Kardon RH, Wall M. Presumed "sulfa allergy" in patients with intracranial hypertension treated with acetazolamide or furosemide: cross-reactivity, myth or reality? <i>Am J Ophthalmol</i>. 2004;138(1):114-118. doi:10.1016/j.ajo.2004.02.019<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acetazolamide-drug-information/abstract-text/15234289/pubmed" id="15234289" target="_blank">15234289</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31248818">
<a name="31248818"></a>Luks AM, Auerbach PS, Freer L, et al. Wilderness Medical Society clinical practice guidelines for the prevention and treatment of acute altitude illness: 2019 update. <i>Wilderness Environ Med</i>. 2019;30(4S):S3-S18. doi:10.1016/j.wem.2019.04.006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acetazolamide-drug-information/abstract-text/31248818/pubmed" id="31248818" target="_blank">31248818</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20591379">
<a name="20591379"></a>Luks AM, McIntosh SE, Grissom CK, et al, “Wilderness Medical Society Consensus Guidelines for the Prevention and Treatment of Acute Altitude Illness,” <i>Wilderness Environ Med</i>, 2010, 21(2):146-55.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acetazolamide-drug-information/abstract-text/20591379/pubmed" id="20591379" target="_blank">20591379</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1894525">
<a name="1894525"></a>Marik PE, Kussman BD, Lipman J, Kraus P. Acetazolamide in the treatment of metabolic alkalosis in critically ill patients. <i>Heart Lung.</i> 1991;20(5, pt 1):455-459.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acetazolamide-drug-information/abstract-text/1894525/pubmed" id="1894525" target="_blank">1894525</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10446816">
<a name="10446816"></a>Mazur JE, Devlin JW, Peters MJ, Jankowski MA, Iannuzzi MC, Zarowitz BJ. Single versus multiple doses of acetazolamide for metabolic alkalosis in critically ill medical patients: a randomized, double-blind trial. <i>Crit Care Med</i>. 1999;27(7):1257-1261.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acetazolamide-drug-information/abstract-text/10446816/pubmed" id="10446816" target="_blank">10446816</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1451021">
<a name="1451021"></a>McWhae JA, Chang J, Lipton JH. Drug-induced fatal aplastic anemia following cataract surgery. <i>Can J Ophthalmol</i>. 1992;27(6):313-315.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acetazolamide-drug-information/abstract-text/1451021/pubmed" id="1451021" target="_blank">1451021</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Mehta.2021">
<a name="Mehta.2021"></a>Mehta A, Emmett M. Treatment of metabolic alkalosis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed June 14, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17667206">
<a name="17667206"></a>Moffett BS, Moffett TI, Dickerson HA. Acetazolamide therapy for hypochloremic metabolic alkalosis in pediatric patients with heart disease. <i>Am J Ther</i>. 2007;14(4):331-335.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acetazolamide-drug-information/abstract-text/17667206/pubmed" id="17667206" target="_blank">17667206</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3211478">
<a name="3211478"></a>Mogk LG, Cyrlin MN. Blood dyscrasias and carbonic anhydrase inhibitors. <i>Ophthalmology</i>. 1988;95(6):768-771. doi:10.1016/s0161-6420(88)33110-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acetazolamide-drug-information/abstract-text/3211478/pubmed" id="3211478" target="_blank">3211478</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16420662">
<a name="16420662"></a>Moviat M, Pickkers P, van der Voort PH, et al, “Acetazolamide-Mediated Decrease in Strong Ion Difference Accounts for the Correction of Metabolic Alkalosis in Critically Ill Patients,” <i>Critical Care</i>, 2006, 10(1):R14.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acetazolamide-drug-information/abstract-text/16420662/pubmed" id="16420662" target="_blank">16420662</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36027559">
<a name="36027559"></a>Mullens W, Dauw J, Martens P, et al; ADVOR Study Group. Acetazolamide in acute decompensated heart failure with volume overload. <i>N Engl J Med</i>. 2022;387(13):1185-1195. doi:10.1056/NEJMoa2203094<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acetazolamide-drug-information/abstract-text/36027559/pubmed" id="36027559" target="_blank">36027559</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NICE.2014">
<a name="NICE.2014"></a>National Institute for Health and Care Excellence (NICE). Drug allergy: diagnosis and management. Clinical guideline. https://wolterskluwercdi.app.box.com/file/801819455255 Updated September 3, 2014. Accessed September 27, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NICE.2012">
<a name="NICE.2012"></a>National Institute for Health and Care Excellence (NICE). Epilepsies: diagnosis and management. Clinical guideline. https://www.nice.org.uk/guidance/cg137. Updated May 12, 2021. Accessed June 9, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12203177">
<a name="12203177"></a>Newton PN, Thai le H, Tip NQ, et al. A randomized, double-blind, placebo-controlled trial of acetazolamide for the treatment of elevated intracranial pressure in cryptococcal meningitis. <i>Clin Infect Dis</i>. 2002;35(6):769-772. doi:10.1086/342299<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acetazolamide-drug-information/abstract-text/12203177/pubmed" id="12203177" target="_blank">12203177</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Pagliaro.2002">
<a name="Pagliaro.2002"></a>Pagliaro LA and Pagliaro AM, eds. <i>Problems in Pediatric Drug Therapy. </i>4th ed. Washington, DC: American Pharmaceutical Association; 2002.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7604446">
<a name="7604446"></a>Parikh JR, Nolan RL, Bannerjee A, et al, “Acetazolamide-Associated Nephrocalcinosis in a Transplant Kidney,” <i>Transplantation</i>, 1995, 59(12):1742-3.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acetazolamide-drug-information/abstract-text/7604446/pubmed" id="7604446" target="_blank">7604446</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Park.2014">
<a name="Park.2014"></a>Park, MK. <i>Park's Pediatric Cardiology for Practitioners</i>. 6th ed. Philadelphia, PA: Elsevier Health Sciences; 2014.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22981259">
<a name="22981259"></a>Per H, Canpolat M, Gumus H, et al. Clinical spectrum of the <i>pseudotumor cerebri</i> in children: etiological, clinical features, treatment and prognosis. <i>Brain Dev</i>. 2013;35:561-568.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acetazolamide-drug-information/abstract-text/22981259/pubmed" id="22981259" target="_blank">22981259</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1524131">
<a name="1524131"></a>Peralta J, Abelairas J, Fernández-Guardiola J. Anaphylactic shock and death after oral intake of acetazolamide. <i>Am J Ophthalmol</i>. 1992;114(3):367. doi:10.1016/s0002-9394(14)71807-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acetazolamide-drug-information/abstract-text/1524131/pubmed" id="1524131" target="_blank">1524131</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22668539">
<a name="22668539"></a>Phillips PH. Pediatric pseudotumor cerebri.<i> Int Ophthalmol Clin</i>. 2012;52(3):51-59, xii.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acetazolamide-drug-information/abstract-text/22668539/pubmed" id="22668539" target="_blank">22668539</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2204147">
<a name="2204147"></a>Piepgras A, Schmiedek P, Leinsinger G, et al, “A Simple Test to Assess Cerebrovascular Reserve Capacity Using Transcranial Doppler Sonography and Acetazolamide,” <i>Stroke</i>, 1990, 21(9):1306-11.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acetazolamide-drug-information/abstract-text/2204147/pubmed" id="2204147" target="_blank">2204147</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22158718">
<a name="22158718"></a>Platt D, Griggs RC. Use of acetazolamide in sulfonamide-allergic patients with neurologic channelopathies. <i>Arch Neurol</i>. 2012;69(4):527-529. doi:10.1001/archneurol.2011.2723<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acetazolamide-drug-information/abstract-text/22158718/pubmed" id="22158718" target="_blank">22158718</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17910297">
<a name="17910297"></a>Pokhrel PK, Loftus SA. Ocular emergencies. <i>Am Fam Physician</i>. 2007;76(6):829-836.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acetazolamide-drug-information/abstract-text/17910297/pubmed" id="17910297" target="_blank">17910297</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11682018">
<a name="11682018"></a>Pollard AJ, Niermeyer S, Barry P, et al, “Children at High Altitude: An International Consensus Statement by an Ad Hoc Committee of the International Society for Mountain Medicine, March 12, 2001,” <i>High Alt Med Biol</i>, 2001, 2(3):389-403.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acetazolamide-drug-information/abstract-text/11682018/pubmed" id="11682018" target="_blank">11682018</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10532366">
<a name="10532366"></a>Portellos M, Buckley EG, Freedman SF. Topical versus oral carbonic anhydrase inhibitor therapy for pediatric glaucoma. <i>J AAPOS</i>. 1998;2(1):43-47.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acetazolamide-drug-information/abstract-text/10532366/pubmed" id="10532366" target="_blank">10532366</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18029269">
<a name="18029269"></a>Rangwala LM, Liu GT. Pediatric idiopathic intracranial hypertension. <i>Survey of Ophthalmology</i>. 2007;52(6):597-617.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acetazolamide-drug-information/abstract-text/18029269/pubmed" id="18029269" target="_blank">18029269</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8740334">
<a name="8740334"></a>Reiss WG and Oles KS, “Acetazolamide in the Treatment of Seizures,” <i>Ann Pharmacother</i>, 1996, 30(5):514-9.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acetazolamide-drug-information/abstract-text/8740334/pubmed" id="8740334" target="_blank">8740334</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28286047">
<a name="28286047"></a>Rialp Cervera G, Raurich Puigdevall JM, Morán Chorro I, et al. Effects of early administration of acetazolamide on the duration of mechanical ventilation in patients with chronic obstructive pulmonary disease or obesity-hypoventilation syndrome with metabolic alkalosis. A randomized trial. <i>Pulm Pharmacol Ther</i>. 2017;44:30-37. doi:10.1016/j.pupt.2017.03.002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acetazolamide-drug-information/abstract-text/28286047/pubmed" id="28286047" target="_blank">28286047</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8340566">
<a name="8340566"></a>Rousseau P and Fuentevilla-Clifton A, “Acetazolamide and Salicylate Interaction in the Elderly: A Case Report,” <i>J Am Geriatr Soc</i>, 1993, 41(8):868-9.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acetazolamide-drug-information/abstract-text/8340566/pubmed" id="8340566" target="_blank">8340566</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1462998">
<a name="1462998"></a>Roy LF, Dufresne LR, Legault L, Long H, Morin C. Acetazolamide in hemodialysis patients: a rational use after ocular surgery. <i>Am J Kidney Dis</i>. 1992;20(6):650-652. doi:10.1016/s0272-6386(12)70235-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acetazolamide-drug-information/abstract-text/1462998/pubmed" id="1462998" target="_blank">1462998</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17070484">
<a name="17070484"></a>Sabri K, Levin AV. The additive effect of topical dorzolamide and systemic acetazolamide in pediatric glaucoma.<i> J AAPOS</i>. 2006;10(5):464-468.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acetazolamide-drug-information/abstract-text/17070484/pubmed" id="17070484" target="_blank">17070484</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32332024">
<a name="32332024"></a>Schmickl CN, Owens RL, Orr JE, Edwards BA, Malhotra A. Side effects of acetazolamide: a systematic review and meta-analysis assessing overall risk and dose dependence. <i>BMJ Open Respir Res</i>. 2020;7(1):e000557. doi:10.1136/bmjresp-2020-000557<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acetazolamide-drug-information/abstract-text/32332024/pubmed" id="32332024" target="_blank">32332024</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7999862">
<a name="7999862"></a>Schwenk MH, Blaustein DA, Wagner JD. The pharmacokinetics of acetazolamide during CAPD. <i>Adv Perit Dial.</i> 1994;10:44-46.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acetazolamide-drug-information/abstract-text/7999862/pubmed" id="7999862" target="_blank">7999862</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7479208">
<a name="7479208"></a>Schwenk MH, St. Peter WL, Meese MG, Singhal PC. Acetazolamide toxicity and pharmacokinetics in patients receiving hemodialysis. <i>Pharmacotherapy.</i> 1995;15(4):522-527.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acetazolamide-drug-information/abstract-text/7479208/pubmed" id="7479208" target="_blank">7479208</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26824595">
<a name="26824595"></a>Shahjouei S, Hanaei S, Habibi Z, Hoseini M, Ansari S, Nejat F. Randomized clinical trial of acetazolamide administration and/or prone positioning in mitigating wound complications following untethering surgeries. <i>J Neurosurg Pediatr</i>. 2016;17(6):659-666. doi: 10.3171/2015.8.PEDS15393<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acetazolamide-drug-information/abstract-text/26824595/pubmed" id="26824595" target="_blank">26824595</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1543228">
<a name="1543228"></a>Shapiro S, Fraunfelder FT. Acetazolamide and aplastic anemia. <i>Am J Ophthalmol</i>. 1992;113(3):328-330. doi:10.1016/s0002-9394(14)71587-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acetazolamide-drug-information/abstract-text/1543228/pubmed" id="1543228" target="_blank">1543228</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-4009338">
<a name="4009338"></a>Shinnar S, Gammon K, Bergman EW Jr, et al, “Management of Hydrocephalus in Infancy: Use of Acetazolamide and Furosemide to Avoid Cerebrospinal Fluid Shunts,” <i>J Pediatr</i>, 1985, 107(1):31-7.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acetazolamide-drug-information/abstract-text/4009338/pubmed" id="4009338" target="_blank">4009338</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15242722">
<a name="15242722"></a>Slatore CG, Tilles SA. Sulfonamide hypersensitivity. <i>Immunol Allergy Clin North Am</i>. 2004;24(3):477-490.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acetazolamide-drug-information/abstract-text/15242722/pubmed" id="15242722" target="_blank">15242722</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6733009">
<a name="6733009"></a>Söderman P, Hartvig P, and Fagerlund C, "Acetazolamide Excretion Into Human Breast Milk," <i>Br J Clin Pharmacol</i>, 1984, 17(5):599-600.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acetazolamide-drug-information/abstract-text/6733009/pubmed" id="6733009" target="_blank">6733009</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9534686">
<a name="9534686"></a>Soler D, Cox T, Bullock P, et al. Diagnosis and management of benign intracranial hypertension. <i>Arch Dis Child</i>. 1998;78:89-94.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acetazolamide-drug-information/abstract-text/9534686/pubmed" id="9534686" target="_blank">9534686</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20721668">
<a name="20721668"></a>Spennato P, Ruggiero C, Parlato RS, et al. <i>Pseudotumor cerebri</i>. <i>Childs Nerv Syst</i>. 2011;27:215-235.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acetazolamide-drug-information/abstract-text/20721668/pubmed" id="20721668" target="_blank">20721668</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21093727">
<a name="21093727"></a>Standridge S. Idiopathic intracranial hypertension in children: a review and algorithm. <i>Pediatric Neurology</i>. 2010;43(6): 377-390.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acetazolamide-drug-information/abstract-text/21093727/pubmed" id="21093727" target="_blank">21093727</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2334313">
<a name="2334313"></a>Stock JG. Sulfonamide hypersensitivity and acetazolamide. <i>Arch Ophthalmol</i>. 1990;108(5):634-635. doi:10.1001/archopht.1990.01070070020005<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acetazolamide-drug-information/abstract-text/2334313/pubmed" id="2334313" target="_blank">2334313</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7327685">
<a name="7327685"></a>Sud RN, Grewal SS. Stevens Johnson syndrome due to Diamox. <i>Indian J Ophthalmol</i>. 1981;29(2):101-103.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acetazolamide-drug-information/abstract-text/7327685/pubmed" id="7327685" target="_blank">7327685</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23011176">
<a name="23011176"></a>Tam B, Chhay A, Yen L, Tesoriero L, Ramanathan R, Seri I, Friedlich PS. Acetazolamide for the management of chronic metabolic alkalosis in neonates and infants. <i>Am J Ther</i>. 2014;21(6):477-481.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acetazolamide-drug-information/abstract-text/23011176/pubmed" id="23011176" target="_blank">23011176</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26587993">
<a name="26587993"></a>ten Hove MW, Friedman DI, Patel AD, Irrcher I, Wall M, McDermott MP; NORDIC Idiopathic Intracranial Hypertension study group. Safety and tolerability of acetazolamide in the idiopathic intracranial hypertension treatment trial. <i>J Neuroophthalmol</i>. 2016;36(1):13-19. doi:10.1097/WNO.0000000000000322<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acetazolamide-drug-information/abstract-text/26587993/pubmed" id="26587993" target="_blank">26587993</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15373844">
<a name="15373844"></a>Tornero P, De Barrio M, Baeza ML, Herrero T. Cross-reactivity among p-amino group compounds in sulfonamide fixed drug eruption: diagnostic value of patch testing. <i>Contact Dermatitis</i>. 2004;51(2):57-62.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acetazolamide-drug-information/abstract-text/15373844/pubmed" id="15373844" target="_blank">15373844</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31706497">
<a name="31706497"></a>Trubiano JA, Ostrov DA, Phillips EJ. Stevens-johnson syndrome and toxic epidermal necrolysis associated with carbonic anhydrase inhibitors: epidemiology, genetics, and insights into mechanisms. <i>J Allergy Clin Immunol Pract</i>. 2019;7(8):2854-2856. doi:10.1016/j.jaip.2019.07.013<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acetazolamide-drug-information/abstract-text/31706497/pubmed" id="31706497" target="_blank">31706497</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9713074">
<a name="9713074"></a>Tzanakis N, Metzidaki G, Thermos K, Spyraki CH, Bouros D. Anaphylactic shock after a single oral intake of acetazolamide. <i>Br J Ophthalmol</i>. 1998;82(5):588. doi:10.1136/bjo.82.5.e584<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acetazolamide-drug-information/abstract-text/9713074/pubmed" id="9713074" target="_blank">9713074</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11985388">
<a name="11985388"></a>Vahedi K, Taupin P, Djomby R, et al; DIAMIG investigators. Efficacy and tolerability of acetazolamide in migraine prophylaxis: a randomised placebo-controlled trial. <i>J Neurol</i>. 2002;249(2):206-211. doi:10.1007/pl00007866<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acetazolamide-drug-information/abstract-text/11985388/pubmed" id="11985388" target="_blank">11985388</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7367929">
<a name="7367929"></a>Vaziri ND, Saiki J, Barton CH, Rajudin M, Ness RL. Hemodialyzability of acetazolamide. <i>South Med J</i>. 1980;73(4):422-423. doi:10.1097/00007611-198004000-00006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acetazolamide-drug-information/abstract-text/7367929/pubmed" id="7367929" target="_blank">7367929</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11149457">
<a name="11149457"></a>Venkatesha SL, Umamaheswara Rao GS. Metabolic acidosis and hyperventilation induced by acetazolamide in patients with central nervous system pathology. <i>Anesthesiology</i>. 2000;93(6):1546-1548. doi:10.1097/00000542-200012000-00035<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acetazolamide-drug-information/abstract-text/11149457/pubmed" id="11149457" target="_blank">11149457</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24756514">
<a name="24756514"></a>Wall M, McDermott MP, Kieburtz KD, et al; NORDIC Idiopathic Intracranial Hypertension Study Group Writing Committee. Effect of acetazolamide on visual function in patients with idiopathic intracranial hypertension and mild visual loss: the idiopathic intracranial hypertension treatment trial. <i>JAMA</i>. 2014;311(16):1641-1651. doi:10.1001/jama.2014.3312<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acetazolamide-drug-information/abstract-text/24756514/pubmed" id="24756514" target="_blank">24756514</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Wandstrat.1995">
<a name="Wandstrat.1995"></a>Wandstrat TL and Phillips J, “Pseudotumor Cerebri Responsive to Acetazolamide,” <i>Ann Pharmacother</i>, 1995, 29(3):318.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30275849">
<a name="30275849"></a>Warrington R, Silviu-Dan F, Wong T. Drug allergy. <i>Allergy Asthma Clin Immunol</i>. 2018;14(Suppl 2):60. doi:10.1186/s13223-018-0289-y<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acetazolamide-drug-information/abstract-text/30275849/pubmed" id="30275849" target="_blank">30275849</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-4847470">
<a name="4847470"></a>Weiss IS, “Hirsutism After Chronic Administration of Acetazolamide,” <i>Am J Ophthalmol</i>, 1974, 78(2):327-8.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acetazolamide-drug-information/abstract-text/4847470/pubmed" id="4847470" target="_blank">4847470</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Weizer.2021">
<a name="Weizer.2021"></a>Weizer JS. Angle-closure glaucoma. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed November 1, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9591933">
<a name="9591933"></a>Yano I, Takayama A, Takano M, et al. Pharmacokinetics and pharmacodynamics of acetazolamide in patients with transient intraocular pressure elevation. <i>Eur J Clin Pharmacol.</i> 1998;54(1):63-68. doi:10.1007/s002280050422<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acetazolamide-drug-information/abstract-text/9591933/pubmed" id="9591933" target="_blank">9591933</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 9268 Version 490.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
